ARVN
HealthcareArvinas, Inc.
$11.17
$-0.30 (-2.62%)
Jan 5, 2026
Price History (1Y)
Analysis
Arvinas, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $820.07 million and 430 employees. The company's industry is characterized by research and development of novel therapeutics. The financial health of Arvinas, Inc. is marked by significant losses, as evident from its net income of -$58,500,000 over the trailing twelve months (TTM). The company has a gross margin of 100.0%, but operating and profit margins are negative at -105.0% and -18.7%, respectively. Returns on equity and assets are also negative at -10.2% and -6.3%, indicating that the company's earnings do not adequately cover its expenses. The balance sheet shows a low debt level of $9.30 million, but a high cash balance of $787.60 million. The valuation context for Arvinas, Inc. is characterized by a negative forward P/E ratio of -3.76 and an EV/EBITDA ratio of 0.42, indicating that the company's market value may not accurately reflect its earnings potential. The revenue growth rate has been negative at -59.1% year-over-year (YoY), suggesting some challenges in the company's business operations.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Visit website →Key Statistics
- Market Cap
- $820.07M
- P/E Ratio
- N/A
- 52-Week High
- $20.63
- 52-Week Low
- $5.90
- Avg Volume
- 2.04M
- Beta
- 1.90
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 430